Side Effects of Weight-Loss Injections: When to Wait and When to See a Doctor

Which Medications Are We Discussing?

In this article, we discuss three main groups of medications together: GLP-1 receptor agonists [such as liraglutide (Saxenda), semaglutide (Ozempic and Wegovy), and dulaglutide (Trulicty)], dual GIP/GLP-1 drugs [tirzepatide (Mounjaro)] and newer medications with multiple incretin effects that are in clinical trials or remain the subject of access discussions in some countries. Although the side-effect profiles of these medications are similar, the intensity of their effects and some specific warnings vary by medication.

The Overall Picture of Side Effects: Most Are Gastrointestinal

The most common side effects of GLP-1-based treatments are nausea, vomiting, diarrhea, constipation, abdominal pain, indigestion, reflux, loss of appetite, fatigue, and headache. Controlled trials have clearly documented the frequency of these side effects.

The lesson from this table is clear: gastrointestinal side effects are also common in the placebo group (because the weight-loss process itself triggers some gastrointestinal symptoms), but they are considerably more common in the active medication group. The key point: most side effects are mild to moderate and temporary. The real priorities are reducing side-effect severity, preventing dehydration, managing the dose correctly, and identifying rare serious conditions early.

The Golden Rule: Titrate the Patient, Not the Dose

The practical approach can be summarized as follows:

What to Do About the Most Common Side Effects

1. Nausea and Early Satiety

Nausea is one of the most common side effects of GLP-1-based medications. It usually becomes more pronounced during the first weeks of treatment or after a dose increase. It is directly associated with slower gastric emptying.

2. Vomiting

Vomiting may occur, particularly after dose escalation. Recurrent vomiting goes beyond a simple side effect; it creates a risk of fluid loss, electrolyte disturbances, and impaired kidney function . Acute kidney injury may therefore also develop alongside vomiting.

With recurrent vomiting, the dose must not be increased, and the next injection must not be given without consulting the physician. Fluids should be taken in small, frequent amounts. Water, ayran, sugar-free electrolyte solutions, or oral rehydration fluids may be preferred. The tirzepatide label states that gastrointestinal side effects such as nausea, vomiting, and diarrhea can lead to acute kidney injury due to fluid loss, and that kidney function should be monitored, particularly with severe symptoms.

3. Diarrhea

Diarrhea is another common side effect. It is usually temporary, but if prolonged it can cause fluid and electrolyte loss. Fluid intake should be increased, and fatty, very sugary, alcohol-containing, or excessively spicy foods should be avoided. Milk and lactose may worsen the condition in some patients; temporary restriction may be tried. Conditions suggesting infection (particularly diarrhea with fever) must be ruled out.

See a doctor if diarrhea lasts longer than 48 hours, there is fever, blood or mucus in the stool, accompanying severe abdominal pain, or signs of dehydration. Older patients and those with kidney disease or heart failure should seek care sooner.

4. Constipation

Constipation occurs particularly because of reduced appetite, eating less, decreased fluid intake, and slower gastrointestinal movement. Management principles:

Daily fluid intake should be increased. Fiber intake should be increased gradually — a sudden, excessive increase in fiber may cause gas/bloating. Vegetables, legumes, oats, whole grains, and fruit may be introduced in a controlled way. Regular walking is important. If necessary, polyethylene glycol, lactulose, or similar stool softeners may be used on a physician's recommendation. The medication list should be reviewed, as iron preparations, opioid painkillers, and some antidepressants can worsen constipation.

5. Reflux, Indigestion, and Heartburn

Because GLP-1 medications slow gastric emptying, they may cause reflux, belching, bloating, and indigestion in some patients. Avoid eating late at night and do not lie down for at least 2–3 hours after eating. Reduce coffee, alcohol, carbonated drinks, chocolate, mint, tomato-based sauces, and fatty foods. Reduce portion sizes; the head of the bed may be raised. A short course of a proton pump inhibitor or H2 blocker may be used if the physician considers it appropriate.

More Serious Side Effects: Which Symptoms Are Warning Signs?

1. Pancreatitis: Severe, Persistent Abdominal Pain

Acute pancreatitis is rare but potentially serious. The labels of GLP-1-based medications carry a pancreatitis warning. Warning symptoms include severe, persistent upper abdominal pain, pain radiating to the back, accompanying nausea and vomiting, fever, and deterioration in general condition.

If these symptoms occur, the medication must not be administered and urgent assessment is required. The tirzepatide label explicitly states that the medication must be discontinued if pancreatitis is suspected, and that the patient must be managed appropriately.

2. Gallbladder Problems: Even Weight Loss Creates Risk

Rapid weight loss may increase the risk of gallstones. An increased risk of gallbladder and biliary tract disease has been reported with GLP-1-based medications. A large meta-analysis published in JAMA Internal Medicine reported that GLP-1 receptor agonists increased the risk of gallbladder/biliary tract disease, but that the absolute risk increase was approximately 27 additional cases per 10.000 person-years of treatment . The risk appears more pronounced with higher doses, longer use, and in studies using the medications for weight loss.

Warning symptoms: right upper abdominal pain, pain that worsens after fatty meals, fever, nausea and vomiting, jaundice, dark urine, pale stools. These symptoms require ultrasound and blood tests to assess for gallstones, gallbladder inflammation, or biliary obstruction.

3. Fluid Loss and Impaired Kidney Function

When nausea, vomiting, and diarrhea persist, the main danger is less the medication itself than dehydration, meaning fluid loss. Particular care is needed in older people, patients with kidney disease, people taking diuretics, and those taking blood pressure medications. Symptoms to watch for include decreased urine output, dry mouth, dizziness, palpitations, fatigue, low blood pressure, and confusion. Monitoring kidney function in patients who develop severe gastrointestinal side effects is among the label recommendations.

4. Hypoglycemia: Critical for People Using Insulin or Sulfonylureas

With GLP-1 medications, when used alone , the risk of serious hypoglycemia is generally low. However, if the patient uses insulin or sulfonylurea diabetes medications, the risk increases markedly. Symptoms include sweating, trembling, palpitations, hunger, dizziness, confusion, and fainting. The tirzepatide label states that the risk of hypoglycemia may increase when used with insulin or a sulfonylurea, and that the doses of those medications may need to be reduced. Therefore, when starting a weight-loss injection in patients with diabetes, attention should extend beyond "weight"; the existing diabetes treatment must also be readjusted.

5. Eye Problems: Diabetic Retinopathy and the NAION Warning

With medications such as semaglutide, a rapid improvement in blood glucose, particularly in patients with preexisting diabetic retinopathy , can temporarily worsen eye findings. The Ozempic label states that diabetic retinopathy complications were reported more frequently in the semaglutide group than in the placebo group.

In addition, a safety assessment by the European Medicines Agency recommended adding NAION (non-arteritic anterior ischemic optic neuropathy), a rare but serious optic nerve disease, to semaglutide product information as a "very rare" side effect. Sudden vision loss or rapidly worsening vision requires medical attention without delay.

Those requiring greater caution include people with longstanding diabetes, diabetic retinopathy, a history of bleeding inside the eye, laser treatment or retinal treatment, and those experiencing sudden changes in vision. An ophthalmologist's assessment before treatment or early in its course is sensible for this group.

6. A History of Medullary Thyroid Cancer and MEN2

The labels of some GLP-1-based medications carry warnings about thyroid C-cell tumors. Although the clinical significance of this risk in humans is unclear, these medications are contraindicated in people with a personal or family history of medullary thyroid cancer or MEN2 syndrome. The tirzepatide label explicitly states this contraindication.

7. Pregnancy, Breastfeeding, and Contraception

These medications must not be used for weight loss during pregnancy. European product information for semaglutide recommends stopping the medication at least 2 months before a planned pregnancy. If pregnancy is detected, the medication must be stopped.

Another important issue with tirzepatide concerns oral contraceptive pills. Because tirzepatide delays gastric emptying, it may affect the absorption of oral contraceptives. For this reason, after starting tirzepatide and after every dose increase, a non-oral contraceptive method or an additional barrier method for 4 weeks is recommended in the FDA label.

8. Before Surgery and Anesthesia

Because GLP-1 medications can slow gastric emptying, the risk of stomach contents entering the lungs (aspiration) during anesthesia may theoretically increase. This is particularly important before endoscopy, sedation, and general anesthesia.

The approach became more nuanced in the 2024 multispecialty guidelines: most patients can continue GLP-1 treatment before a procedure; however, a liquid diet for 24 hours, adjustments to the anesthesia plan, or, rarely, postponement of the procedure may be considered for high-risk patients. Risk is greater in people who have recently started treatment, are undergoing dose escalation, have significant gastrointestinal symptoms, or have a high risk of gastroparesis.

9. The Debate About Mood and Suicidal Thoughts

Concerns about suicidal thoughts or psychiatric side effects have periodically been discussed in connection with GLP-1 medications. However, the FDA's comprehensive 2026 assessment examined data from more than 100 thousand patients in 91 placebo-controlled trials and found no increase in suicidal thoughts/behavior or psychiatric side effects with GLP-1 receptor agonists.

Nevertheless, this principle applies in practice: patients with a history of depression, eating disorders, or suicidal thoughts should be monitored closely. If significant mood changes, increased anxiety, or thoughts of self-harm develop, the treatment team should be contacted promptly. A person experiencing mental health problems should not hesitate to seek support from a healthcare professional.

Side-Effect Management Algorithm

Counterfeit, Unlicensed, and "Compounded" Products: A Major Danger of the New Era

As these medications have become popular, the use of counterfeit, unlicensed, incorrectly dosed products or those prepared under the name "compounded" has also increased. The FDA has announced reports, particularly with compounded semaglutide and tirzepatide products, of dosing errors, hospital visits, overdose, nausea and vomiting, fainting, dehydration, acute pancreatitis, and gallstones . It has also stated that different salt forms, such as semaglutide sodium or acetate, cannot be considered equivalent to approved products.

Muscle Loss: Losing Weight Without Losing Strength

Most weight loss with these medications comes from fat mass; however, some loss of lean mass is possible during any effective weight-loss process. This is particularly important in older people, patients with cancer, those with muscle loss, people with inadequate protein intake, and inactive individuals . Large studies have shown that weight loss comes mainly from fat mass, but changes in muscle/lean mass can vary by patient. Expert recommendations emphasize increased protein intake, resistance exercise, and assessment of sarcopenia risk, particularly in older and frail patients.

The scale alone is not enough. Waist circumference, muscle strength, walking capacity, and nutritional status should also be monitored. This approach is vital, particularly in patients over 65 and those with cancer.

Checklist Before Starting Treatment

Before starting a weight-loss injection, the patient should be assessed in their full medical context, not just by their weight. Critical questions to ask before starting:

Although baseline laboratory assessment varies by patient, the following tests may be considered: fasting glucose and HbA1c, kidney function, liver function, electrolytes, lipid profile, and TSH when needed. Eye assessment in patients with diabetes, ultrasound if there is a history of gallbladder problems, and assessment of muscle strength and nutrition if there is a risk of sarcopenia may be added.

Special Caution in Patients With Cancer

In oncology practice, these medications require particular care. This is because weight loss in patients with cancer is not always a "positive" goal. In some patients, weight loss may mean cachexia, muscle loss, reduced treatment tolerance, and deterioration in general condition. Therefore, if GLP-1 or similar medications are being considered for patients receiving active cancer treatment, the following questions must be answered:

Is the patient truly receiving treatment because of obesity-related metabolic risk? Or is there already weight loss due to cancer or its treatment? Is muscle mass being preserved? Does the risk of nausea/diarrhea overlap with that from chemotherapy, immunotherapy, or targeted therapy? Is oral intake adequate? Does the patient have gastrointestinal obstruction, peritoneal disease, or pancreatic/biliary tract problems?

Particularly in patients with advanced cancer, cachexia, marked loss of appetite, sarcopenia, a risk of bowel obstruction, or active severe gastrointestinal side effects , these medications should be used only in highly selected situations following multidisciplinary assessment. In circumstances such as obesity developing after early-stage breast cancer, a decision can be made by considering the patient's oncological follow-up together with their obesity risk profile — but these decisions must be made with the oncologist's knowledge.

Conclusion: Powerful Treatment Requires Close Monitoring

GLP-1- and GIP/GLP-1-based weight-loss medications have ushered in a new era of obesity treatment. However, it is wrong to see these medications as "easy weight-loss injections." They have serious metabolic effects, can be highly beneficial in the right patient, and can cause problems in the wrong patient or with incorrect dose management. They are medical treatments.

The most common side effects involve the gastrointestinal system and are often manageable. However, symptoms such as severe abdominal pain, recurrent vomiting, jaundice, vision loss, severe fluid loss, hypoglycemia, or an allergic reaction must never be dismissed as a "normal side effect." Success with these treatments should not be measured only by the weight lost. True success means preserving muscle while losing fat, improving metabolic health, managing side effects, keeping the patient safe, and making the medication part of a long-term health plan.

This article was created using various editorial tools, including artificial intelligence, as part of the process. It was reviewed by human editors before publication. The information in this article is for informational purposes and does not replace personal medical advice. Weight-loss medications must be used under a physician's supervision, with a prescription and regular follow-up.